FDA Approves First Treatment for HSCT-Associated Thrombotic Microangiopathy
The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults and children aged 2 years and older, marking…